12th Feb: Efficacy of AC102 for the Preservation of Residual Hearing following Cochlear Implantation Dr. Michael Nieratschker from Allgemeines Krankenhaus Medical University of Vienna, Austria will present preclinical results performed in a model of electrode...
At the start of the Phase II clinical trial, AudioCure Pharma GmbH will provide their newest insights on the mode of action of lead candidate AC102 at the 2nd Summit in Boston from 20-23 June 2022. AC102 is AudioCure’s clinical Phase I tested lead candidate for...
The FDA has granted orphan drug designation to AC102, concluding that AudioCure’s lead compound may become of significant benefit for patients suffering with the rare and chronically debilitating disease of sudden sensorineural hearing loss (SSNHL). Comprehensive...
